Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Operating Expenses: 2011-2024

Historic Operating Expenses for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $80.6 million.

  • Adma Biologics' Operating Expenses rose 22.94% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.3 million, marking a year-over-year increase of 38.47%. This contributed to the annual value of $80.6 million for FY2024, which is 19.70% up from last year.
  • Latest data reveals that Adma Biologics reported Operating Expenses of $80.6 million as of FY2024, which was up 19.70% from $67.3 million recorded in FY2023.
  • Adma Biologics' Operating Expenses' 5-year high stood at $80.6 million during FY2024, with a 5-year trough of $45.8 million in FY2020.
  • Its 3-year average for Operating Expenses is $74.2 million, with a median of $74.6 million in 2022.
  • As far as peak fluctuations go, Adma Biologics' Operating Expenses rose by 29.89% in 2021, and later declined by 9.81% in 2023.
  • Over the past 5 years, Adma Biologics' Operating Expenses (Yearly) stood at $45.8 million in 2020, then climbed by 29.89% to $59.5 million in 2021, then increased by 25.33% to $74.6 million in 2022, then fell by 9.81% to $67.3 million in 2023, then grew by 19.70% to $80.6 million in 2024.